What is Hereditary Breast and Ovarian Cancer (HBOC)?
Most cases of breast and ovarian cancer happen by chance. However in some situations, individuals can have harmful changes (called pathogenic variants) in specific genes that convey an increased risk of developing breast and ovarian cancers. These pathogenic variants are inherited (passed from parent to child) and can be detected by genomic testing. A strong family history of breast, ovarian and/or colorectal cancers may suggest pathogenic familial variants.
Approximately 5-10% of breast cancers are due to inherited genetic variants and at least 20%of ovarian cancers are also thought to be hereditary. Genomic testing of BRCA1, BRCA2 and other cancer susceptibility genes can be used to identify patients and relatives with an increased lifetime risk of these and other cancers due to inherited pathogenic variants. Having a genetic variant for HBOC does not guarantee cancer development but elevates the lifetime risk substantially.

Testing for these genetic variants is important is important in two main settings. Diagnostic testing is performed for individuals with a diagnosis or personal history of cancer, and predictive testing is performed in unaffected individuals to determine the future risk of cancer. Awareness of family cancer risk can alter medical care for individuals and their families.
Who should consider testing?
Genetic testing for HBOC might be recommended if you have:
- A family history of breast or ovarian cancer, especially at young ages.
- Multiple family members affected by these cancers.
- A known BRCA pathogenic variant in your family or other familial variant.
- Personal history of breast cancer, particularly if diagnosed under 60, or if it's triple-negative breast cancer.
- Ashkenazi Jewish ancestry, which has a higher prevalence of BRCA pathogenic variants.
- Male breast cancer in the family.
Other reasons for genetic testing may also be considered, and your healthcare provider can help you understand whether you may be a candidate for testing.
Our panels
Genomic Diagnostics offers multiple gene tests and panels for hereditary breast and ovarian cancer.
Genetic counselling is required by our national accreditation body for all tests as the results can have important medical and psychological implications for both you and your family. This counselling can be performed by a qualified genetic counsellor or a medical specialist.
Your request for testing may come from either a general practitioner or a medical specialist, we accept both. There are different pathways to obtain testing, depending on your requesting practitioner. This is due to the requirement for genetic counselling and Medicare.
A specialist can request any of our hereditary breast and ovarian cancer tests. They may do so to direct the use of specific treatments if you currently have cancer, guide risk-reducing surgery, and also to guide in the testing of at-risk family members. Often you will be covered by Medicare for your test.
Medicare does not cover any requests originating with a general practitioner (GP) and GP's are also unable to perform the genetic counselling which must accompany all tests. To enable you to access breast and ovarian cancer genetic testing through your general practitioner, Genomic Diagnostics offers a combined testing and genetic counselling package. This package includes dedicated pre-and post-test genetic counselling sessions with a qualified genetic counsellor along with genetic testing. The counsellors will guide you through what testing means, the potential implications for you and your family members, and what your results mean. This option is often chosen by unaffected individuals.
Patients' process
Step 1
Your doctor will discuss hereditary breast and ovarian cancer testing with you, ensuring you understand the process, cost (if any) and implications. They will provide a dedicated request form to which you will need to sign your consent to proceed.
Step 2
Medicare may not cover the cost of this test. If you need to pay for the test, do so here, prior to having your blood taken at your local Healius Pathology collection centre. Write the receipt number on the request form.
Step 3
If your request has been signed by a GP or your specialist has requested external genetic counselling, your details will be passed onto our genetic counselling partners, who will contact you directly to arrange a pre-test genetic counselling session.
Step 4
Your results will be delivered to your doctors within 4 – 5 weeks after completion of pre-test genetic counselling. If your original request was signed by a general practitioner, these results will also be sent to the genetic counsellor, who will conduct a post-test counselling session with you.
FAQ
The BRAoVO panel looks at 13 high and moderate high-risk genes linked to an increased lifetime risk of breast and ovarian cancers, as well as other cancers such as prostate and pancreatic cancer. This includes the well-known BRCA1 and BRCA2 genes.
The BRAoVO Plus panel expands the analysis to 18 genes, which may be particularly relevant for:
- ovarian cancer patients
- breast cancer patients with a family history that includes ovarian cancer
- families with a mix of cancers, including breast, ovarian and colorectal cancer.
If a specific genetic variant has already been identified in your family, you can choose single variant testing instead of a full panel.
Genomic testing in breast and ovarian cancer can be clinically useful in two main areas:
- Diagnostic testing for individuals with a diagnosis or personal history of cancer, to help guide treatment and medical management
- Predictive testing for people without cancer, to determine their future cancer risk, usually when there is a family history of cancer, and especially if a known gene change runs in the family. This may guide medical management to reduce cancer risk.
Understanding inherited cancer risks can help shape medical care for both you and your family.
Genetic counselling involves discussing benefits,limitations and the possible implications of genetic testing. It must becompleted before testing, either with your referring specialist or a qualifiedgenetic counsellor.
Because genetic results can have medical andemotional impacts on both you and your family, national regulations requirecounselling before testing. After counselling, you’ll need to provide informedconsent before proceeding. If you choose not to proceed, you can stop theprocess at this stage.
Your results will be sent to your clinician orgenetic counsellor, who will discuss them with you along with the next steps.Possible findings include:
Positive result– also known as ‘Pathogenic variant detected’. This means a gene change wasidentified that is known to increase your cancer risk. It does not mean youwill develop cancer but it may impact your medical management. The result can beshared with your relatives who may then consider testing.
Negative result– also known as ‘No pathogenic variant detected’. This means you do not have aharmful change in any of the genes tested. However, this does not eliminate allcancer risk, as other genetic and non-genetic factors can contribute.
Variant of unknown significance (VUS)detected – this means a gene change was identified however its impact onhereditary cancer risk is not yet understood. This finding will not change yourongoing medical care.
If you test positive, your parents, siblings, andchildren may also be at risk. They may want to consider testing for thespecific gene variant to understand their own risks. Speak with your clinicianmore about this and refer also to the ‘Informing Family Members’ fact sheet.
Testing for multiple genes takesapproximately 4 weeks. Testing will only begin once you have completed your pre-testgenetic counselling session.
The test is simple. It requires two blood samples,taken 10 minutes apart at your nearest Healius collection centre. Noappointment is necessary—you can attend any centre, any time, any day.
If you get a positive result, the result isconfirmed by testing of the blood from the second collection. This is an addedquality step to ensure there has been no sample identification issues duringthe testing process.
Our laboratory uses highly sensitive, advancedtechnology to analyse your DNA, ensuring accurate results.
- Medicare covers the test in many cases, but you must be referred by a specialist and meet specific eligibility criteria. Your doctor will confirm if you qualify.
- Private health insurance does not cover genetic testing.
Yes. Your genetic test results are confidential andprotected. However, some types of life insurance may be affected by genetictest results. More information is provided on the ‘Life Insurance’ Fact Sheet.
You may change your mind abouttesting at any stage during the process. If you have paid privately for a testbut decide not to proceed, you may be eligible for a partial refund. Administrative costs may apply.
Please call our Customer Care team on 1800 822 999 to discuss a refund if you do not proceed with testing. Administrative costs may apply.
Why screen patients for Hereditary Breast and Ovarian Cancer (HBOC)?
Approximately 5-10% of breast cancers are due to inherited genetic variants and at least 20%of ovarian cancers are also thought to be hereditary. Genomic testing of BRCA1, BRCA2 and other cancer susceptibility genes can be used to identify patients and relatives with an increased lifetime risk of these and other cancers due to inherited pathogenic variants.
Individuals with BRCA1/2 pathogenic variations face significantly elevated risks for breast cancer (up to 72% for BRCA1 and slightly lower for BRCA2 by age 80) and ovarian cancer (up to 44% for BRCA1). Other cancers like prostate, pancreatic, and melanoma are also associated but to a lesser extent.
Genetic testing could be considered when there is:
- A strong family history of breast or ovarian cancer, especially at younger ages
- Multiple family members affected or cases of bilateral breast cancer or both breast and ovarian cancer in a single individual
- Early onset breast cancer
- Male breast cancer
- Ashkenazi Jewish ancestry where BRCA pathogenic variants are more prevalent.
When is testing useful?
Testing for harmful changes in specific genes that convey an increased risk of developing breast and ovarian cancers can help in the following ways:
- Provide specific information on prognosis and lifetime risk of cancer
- Direct the use of specific treatments
- Direct more frequent screening and consideration of prophylactic risk-reducing surgery, for example mastectomy, and medications
- Guide testing of at-risk family members
- Assist couples with reproductive decision making
- Provide an explanation for personal or family history of cancer
Our panels
Genomic Diagnostics offers multiple gene tests and panels for hereditary breast and ovarian cancer.
Genetic counselling is required by our national accreditation body for all tests as the results can have important medical and psychological implications for both you and your family. This counselling can be performed by a qualified genetic counsellor or a medical specialist.
Genomic Diagnostics offer two pathways by which patients may be tested for hereditary breast and ovarian cancer variants - through either a specialist request or through a general practitioner request.
A specialist can request any of our hereditary breast and ovarian cancer tests.
Our BRAoVOTM 13 gene panel tests for genetic variants in a number of high and moderate risk genes that have been demonstrated to increased the risk of breast and/or ovarian cancer. The BRAoVOTM Plus panel looks at 18 genes, adding to our BRAoVOTM panel the MMR genes and EPCAM from the Lynch syndrome panel. This panel is important for breast cancer patients with a family history that includes ovarian cancer and is also useful for families where there is a mixed cancer picture of breast +/- ovarian +/- colorectal cancer.
Testing of the BRCA1 and BRCA2 genes can be used to determine eligibility for olaparib therapy in some patients with ovarian, breast or prostate cancer, and single gene testing is important for family members where there is a known familial variant.
A general practitioner may only request our BRAoVOTM testing and counselling package. Medicare does not cover any requests signed by a general practitioner and they are also unable to perform the genetic counselling which must accompany all tests. Through the provision of a package, we enable patients to undergo testing and provide dedicated sessions with a qualified genetic counsellor both before and after genetic testing. They will provide detailed information to the patients on what testing means, the potential implications for the patient and their family members, and what their results mean.
Steps
Step 1
Discuss your patient’s family history of cancer with them and whether testing for hereditary breast and ovarian cancer testing would be beneficial. Complete a dedicated request form, ensuring they understand the process, cost (if any) and implications. If pre-test genetic counselling has been undertaken, ensure the patient signs the form.
Step 2
Patients who are not covered by Medicare will need to prepay for the test here and note their receipt number of the request form. They then attend their most convenient collection centre with their signed request form.
Step 3
If the patient is to undertake pre-test genetic counselling through one of Genomic Diagnostics’ qualified genetic counselling partners, their details will be passed on and the genetic counsellors will contact the patient directly to arrange a pre-test genetic counselling session.
Step 4
Results are delivered to you by your preferred method approximately 4 weeks after the patient has had genetic counselling performed or their blood collected (if you performed the latter). For all GP requests, the results are sent directly to the genetic counsellors also and a post-test counselling session arranged.
FAQ
Risk prediction models can be used to calculate the likelihood of carrying a variant in selected cancer risk genes. These are evidence-based tools that can assist in determining whether genomic testing should be performed.
The models available for HBOC are:
- Manchester Score – from St Mary’s Hospital in Manchester.
- BOADICEA – from Cambridge University – canrisk.org
- Penn II Risk Model – from the University of Pennsylvania – pennmodel2.pmacs.upenn.edu/penn2
More recently, eviQ guidelines have been accepted as enabling patients to meet the Medicare criteria - https://www.eviq.org.au/cancer-genetics/adult/genetic-testing-for-heritable-pathogenic-variants/620-brca1-brca2-and-palb2-truncating-variants
Genetic testing for inherited cancer is a complex process that generates results that can have significant medical and psychological implications for patients and their families. As part of our laboratory accreditation, Genomic Diagnostics must ensure that patients receive appropriate genetic counselling for this type of testing.
Genetic counselling involves discussing benefits, limitations and the possible consequences of the genetic testing to be performed. It can be provided by a specialist or a qualified genetic counsellor and must be undertaken before the patient undergoes testing.
The Medicare schedule currently contains three item numbers relevant to hereditary breast and ovarian cancer genetic testing.
These are only rebatable if requested through a specialist and if the patient meets the criteria set out in them.
In summary:
MBS #73295 – for patients with ovarian/fallopian/peritoneal/breast cancer for access to the drug olaparib.
MBS # 73296 – for patients with a personal history of cancer AND have a >10% chance of having a familial variant based on clinical and family history criteria.
MBS #73297 – predictive familial cancer test for a single gene variant where a family member has been identified as having this variant. A report from the family member stating the exact details of the variant must be supplied.
Genetic testing for inherited cancer is often accessed through state-funded Familial Cancer Services at major public hospitals, and private medical specialists and clinics with an interest in inherited cancers. These options continue to be available.
Unfortunately, due to increased awareness of testing, wait times for pre-test counselling and genetic testing can be very long (6 -12 months) and can be even longer for patients in regional and remote areas.
While testing through public and private services can be free of charge this is not always the case, as patients may not meet the eligibility requirements of the medical service or Medicare criteria.
The Genomic Diagnostic option for breast and ovarian cancer genetic testing requested by GPs provides medically referred, rapid and safe access for patients looking for an alternative offering to traditional pathways to testing. We recommend that you discuss with your patient which is the right option for them.